EP 1237557 A1 20020911 - GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE
Title (en)
GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE
Title (de)
GALENISCHE PRÄPARATIONEN VON DAPSON UND VERWANDTEN SULPHONEN SOWIE METHODE ZUR THERAPEUTISCHEN UND PRÄVENTIVEN BEHANDLUNG VON ERKRANKUNGEN
Title (fr)
PREPARATIONS GALENIQUES DE DAPSONE ET DE SULFONES APPARENTES ET PROCEDE DE TRAITEMENT THERAPEUTIQUE ET PROPHYLACTIQUE DE LA MALADIES
Publication
Application
Priority
- US 0033138 W 20001207
- US 16972799 P 19991208
Abstract (en)
[origin: WO0141772A1] Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.
IPC 1-7
IPC 8 full level
A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/136 (2006.01); A61K 31/145 (2006.01); A61K 31/16 (2006.01); A61K 31/167 (2006.01); A61K 31/185 (2006.01); A61K 31/426 (2006.01)
CPC (source: EP)
A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/205 (2013.01); A61K 9/2059 (2013.01); A61K 9/2866 (2013.01); A61K 31/136 (2013.01); A61K 31/145 (2013.01); A61K 31/16 (2013.01); A61K 31/167 (2013.01); A61K 31/185 (2013.01); A61K 31/426 (2013.01); Y02A 50/30 (2018.01)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0141772 A1 20010614; AU 2066401 A 20010618; EP 1237557 A1 20020911
DOCDB simple family (application)
US 0033138 W 20001207; AU 2066401 A 20001207; EP 00983981 A 20001207